Piper Sandler lowered the firm’s price target on Allogene Therapeutics (ALLO) to $7 from $9 and keeps an Overweight rating on the shares. The firm notes the company reported its Q1 2025 earnings where the next data update from the ALPHA3 trial of cema-cel in the first line consolidation setting has been pushed to the first half of 2026 from mid-2025. Main reasons for the delay include inadequate staffing at sites and patient retention for initial MRD testing.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Positive Outlook on Allogene Therapeutics Amid ALPHA3 Trial Delays and Market Expansion Potential
- Allogene downgraded to Market Perform from Outperform at Citizens JMP
- Allogene Therapeutics Advances Clinical Trials and Extends Cash Runway
- Allogene Therapeutics reports Q1 EPS (28c), consensus (29c)
- ALLO Upcoming Earnings Report: What to Expect?